Discover the microscopic organisms that inhabit our bodies and new microbiome-based treatment strategies in the clinic.
Discover how doctors and patients can recognize and safely manage an overstimulated or misdirected immune response with Dr. Jeffrey S. Weber of NYU Langone Health.
Discover the full potential of genome-based medicine with genomic and genetic testing for cancer risk and tumor assessment with Corrie Painter, Ph.D., and Eliezer Van Allen, M.D.
Discover antibody-based imaging strategies that help doctors visualize patients’ tumors and immune cells in real-time via PET scans.
Dr. Padmanee Sharma of MD Anderson discusses what breakthroughs and advances might lie ahead for the field of cancer immunotherapy in 2020.
Dr. Michel Sadelain of Memorial Sloan Kettering highlights a revolutionary new treatment approach—CAR T cell immunotherapy—that he helped pioneer.
Brendan Connors and his oncologist Dr. Michael Postow of Memorial Sloan Kettering discuss the importance of communication between patient and doctor throughout immunotherapy treatment.
Dr. Patrick Hwu of the MD Anderson highlights the promise and potential of combination immunotherapies and how biomarkers can be used to guide these strategies.
Dr. Elizabeth M. Jaffee of Johns Hopkins University discusses cancer immunotherapy’s ongoing efforts to overcome the challenges ahead and enable immunotherapy to benefit even more people with cancer.
Caregivers Casey Zmudzinski and Benny Juarez, and cancer veteran Kristin Kleinhofer, discuss how they advocate for the best care possible for their loved ones.
Dr. Matthew Hellmann of Memorial Sloan Kettering Cancer Center discusses new FDA approvals, clinical trials, and potential treatments for patients with small cell lung cancer.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
This September for Childhood Cancer Awareness Month, we look at how we’re working toward a future immune to childhood cancer.
This September for Blood Cancer Awareness Month, we look at how we’re working toward a future immune to leukemia, lymphoma, and multiple myeloma.